Corvus Pharmaceuticals Inc (CRVS) - News Archive

Corvus Pharmaceuticals recently presented interim data from its Phase 1b/2 clinical trial evaluating ciforadenant as a potential first-line therapy for patients suffering from metastatic renal cell carcinoma (RCC). This...

Corvus Pharmaceuticals has recently announced favorable data from the first three cohorts of its placebo-controlled Phase 1 clinical trial of Soquelitinib, targeting atopic dermatitis. These findings are detailed amidst...

Soquelitinib Shines in Phase 1 Trial for Atopic Dermatitis: Promising Safety and Efficacy Profile Unveiled In a significant leap forward in the management of atopic dermatitis, Corvus Pharmaceuticals has announced promi...

: The preliminary results from a placebo-controlled Phase 1 clinical trial evaluating Soquelitinib, an investigational treatment for atopic dermatitis, have been released by Corvus Pharmaceuticals. This report details t...

Corvus Pharmaceuticals Inc. has recently made strides in cancer immunotherapy research with the publication of seminal biochemistry and preclinical data concerning its investigational drug, Soquelitinib. These findings...

In recent developments, Corvus Pharmaceuticals has unveiled significant new preclinical data that underscores the potential of Soquelitinib in treating systemic sclerosis. This condition, an autoimmune disease character...

Corvus Pharmaceuticals Secures FDA Fast Track Designation for Soquelitinib in Relapsed or Refractory Peripheral T-cell Lymphoma; Phase 3 Trial Set to Commence In a significant advancement for the treatment of peripheral...

The recent publication of preclinical data in Science Signaling has illuminated the innovative potential of Soquelitinib, a selective inhibitor targeting Interleukin-2-inducible T-cell kinase (ITK), in the realm of infl...

Corvus Pharmaceuticals Announces Successful Pricing of $30.6 Million Registered Direct OfferingBURLINGAME, Calif., May 02, 2024 - Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company,...

Corvus Pharmaceuticals, a noteworthy biopharmaceutical entity, has announced the commencement of a placebo-controlled Phase 1 clinical trial of soquelitinib, its proprietary selective inhibitor of interleukin-2-inducibl...

In recent years, the field of oncology has witnessed significant advancements in the development of targeted therapies. As part of this trend, Corvus Pharmaceuticals, a renowned biopharmaceutical company, has received o...

In a recent press release, Corvus Pharmaceuticals has presented new interim data from its Phase 1/1b clinical trial for soquelitinib (formerly known as CPI-818). The data reveals encouraging anti-tumor activity and dura...